

David C Johnson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7196504/publications.pdf>

Version: 2024-02-01

35
papers

1,351
citations

516215

16
h-index

476904

29
g-index

36
all docs

36
docs citations

36
times ranked

2033
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate cancer. Nature Reviews Disease Primers, 2021, 7, 9.	18.1	434
2	Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging. European Urology, 2019, 75, 712-720.	0.9	187
3	Preoperatively Misclassified, Surgically Removed Benign Renal Masses: A Systematic Review of Surgical Series and United States Population Level Burden Estimate. Journal of Urology, 2015, 193, 30-35.	0.2	182
4	Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity. BJU International, 2014, 114, 221-228.	1.3	75
5	Improving Couples' Quality of Life Through a Web-Based Prostate Cancer Education Intervention. Oncology Nursing Forum, 2015, 42, 183-192.	0.5	60
6	Nutritional predictors of complications following radical cystectomy. World Journal of Urology, 2015, 33, 1129-1137.	1.2	48
7	Integrating Patient Preference into Treatment Decisions for Men with Prostate Cancer at the Point of Care. Journal of Urology, 2016, 196, 1640-1644.	0.2	46
8	Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials. Journal of Urology, 2018, 199, 43-52.	0.2	37
9	Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 9.e1-9.e9.	0.8	37
10	Predicting Pathological Tumor Size in Prostate Cancer Based on Multiparametric Prostate Magnetic Resonance Imaging and Preoperative Findings. Journal of Urology, 2021, 205, 444-451.	0.2	30
11	Surgical Advances in Bladder Cancer. Urologic Clinics of North America, 2015, 42, 235-252.	0.8	26
12	Predicting Short-term Outcomes After Radical Cystectomy Based on Frailty. Urology, 2019, 133, 25-33.	0.5	24
13	Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection. Cancer, 2019, 125, 2955-2964.	2.0	21
14	Association between renal mass biopsy and upstaging to perinephric fat involvement in a contemporary cohort of patients with clinical T1a renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 527.e13-527.e19.	0.8	18
15	Detection of Upper Tract Urothelial Malignancies by Computed Tomography Urography in Patients Referred for Hematuria at a Large Tertiary Referral Center. Urology, 2017, 102, 31-37.	0.5	17
16	Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus: Trends and effect on overall survival. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 577.e9-577.e16.	0.8	17
17	Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. European Urology, 2022, 5, 544-552.	2.6	16
18	Longitudinal Associations Between Healthcare Resources, Policy, and Firearm-Related Suicide and Homicide from 2012 to 2016. Journal of General Internal Medicine, 2020, 35, 2043-2049.	1.3	16

#	ARTICLE	IF	CITATIONS
19	Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 78.e21-78.e28.	0.8	15
20	Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelines. <i>World Journal of Urology</i> , 2019, 37, 1157-1164.	1.2	14
21	Positive surgical margins at radical prostatectomy in the United States: Institutional variations and predictive factors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 1.e17-1.e23.	0.8	7
22	Perioperative Chemotherapy. <i>Urologic Clinics of North America</i> , 2013, 40, 183-195.	0.8	5
23	Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 79.e19-79.e26.	0.8	5
24	The association between N-methylnaltrexone, a peripherally acting mu-opioid receptor antagonist, and clinical outcomes in patients undergoing robotic-assisted radical cystectomy. <i>World Journal of Urology</i> , 2020, 38, 3113-3119.	1.2	5
25	Variation in surgical treatment patterns for patients with prostate cancer in the United States: Do patients in academic hospitals fare better?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 63-70.	0.8	3
26	Focal Therapy Should Not Be Considered for Men with Gleason Grade Group 3-5 Prostate Cancer. <i>European Urology Focus</i> , 2020, 6, 203-204.	1.6	2
27	Improving Shared Decision Making in Latino Men With Prostate Cancer: A Thematic Analysis. <i>MDM Policy and Practice</i> , 2021, 6, 238146832110141.	0.5	2
28	Using spatial tracking with magnetic resonance imaging/ultrasound-guided biopsy to identify unilateral prostate cancer. <i>BJU International</i> , 2020, 125, 399-406.	1.3	1
29	Modeling financial outcomes and quantifying risk in episode-based payment models. <i>American Journal of Managed Care</i> , 2021, 27, e278-e286.	0.8	1
30	Editorial Comment. <i>Urology</i> , 2014, 84, 378-379.	0.5	0
31	Urinary Reconstruction after Radical Cystectomy. <i>Journal of Urology</i> , 2016, 196, 979-980.	0.2	0
32	Author Reply. <i>Urology</i> , 2017, 102, 36-37.	0.5	0
33	Where there is smoke, there is not always fire. <i>Cancer</i> , 2018, 124, 2276-2277.	2.0	0
34	Editorial Comment. <i>Journal of Urology</i> , 2018, 199, 96-96.	0.2	0
35	Reducing decisional conflict in men making treatment decisions on newly diagnosed localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 106-106.	0.8	0